Discovery by a Proteomic Approach of Possible Early Biomarkers of Drug-induced Nephrotoxicity in Medication-overuse Headache

Overview

Journal J Headache Pain

Publisher Biomed Central

Date 2013 Apr 10

PMID 23565828

Citations 9

Authors

Elisa Bellei

Emanuela Monari

Aurora Cuoghi

Stefania Bergamini

Simona Guerzoni

Michela Ciccarese

Tomris Ozben

Aldo Tomasi

Luigi Alberto Pini

Affiliations

Soon will be listed here.

Abstract

Background: Medication-overuse headache (MOH) is a chronic headache condition that results from the overuse of analgesics drugs, triptans, or other antimigraine compounds. The epidemiology of drug-induced disorders suggests that medication overuse could lead to nephrotoxicity, particularly in chronic patients. The aim of this work was to confirm and extend the results obtained from a previous study, in which we analyzed the urinary proteome of 3 MOH patients groups: non-steroidal anti-inflammatory drugs (NSAIDs), triptans and mixtures abusers, in comparison with non-abusers individuals (controls).

Methods: In the present work we employed specialized proteomic techniques, namely two-dimensional gel electrophoresis (2-DE) coupled with mass spectrometry (MS), and the innovative Surface-Enhanced Laser Desorption/Ionization Time-of-Flight mass spectrometry (SELDI-TOF-MS), to discover characteristic proteomic profiles associated with MOH condition.

Results: By 2-DE and MS analysis we identified 21 over-excreted proteins in MOH patients, particularly in NSAIDs abusers, and the majority of these proteins were involved in a variety of renal impairments, as resulted from a literature search. Urine protein profiles generated by SELDI-TOF-MS analysis showed different spectra among groups. Moreover, significantly higher number of total protein spots and protein peaks were detected in NSAIDs and mixtures abusers.

Conclusions: These findings confirm the presence of alterations in proteins excretion in MOH patients. Analysis of urinary proteins by powerful proteomic technologies could lead to the discovery of early candidate biomarkers, that might allow to identify MOH patients prone to develop potential drug overuse-induced nephrotoxicity.

Citing Articles

Candidate Genes and Proteomic Biomarkers of Serum and Urine in Medication-Overuse Headache.

Shnayder N, Sharavii V, Petrova M, Moskaleva P, Pozhilenkova E, Kaskaeva D Int J Mol Sci. 2021; 22(16).

PMID: 34445731 PMC: 8396559. DOI: 10.3390/ijms22169024.

Urinary Proteomics Reveals Promising Biomarkers in Menstrually Related and Post-Menopause Migraine.

Bellei E, Bergamini S, Rustichelli C, Monari E, Dal Porto M, Fiorini A J Clin Med. 2021; 10(9).

PMID: 33923220 PMC: 8123166. DOI: 10.3390/jcm10091854.

Identification of Novel Biomarkers for Predicting Kidney Injury Due to Drugs Using "Omic" Strategies.

Awdishu L, Atilano-Roque A, Tuey S, Joy M Pharmgenomics Pers Med. 2020; 13:687-705.

PMID: 33293850 PMC: 7719321. DOI: 10.2147/PGPM.S239471.

Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-overuse headache.

Pellesi L, Bellei E, Guerzoni S, Cainazzo M, Baraldi C, Monari E BMC Neurol. 2019; 19(1):239.

PMID: 31623575 PMC: 6798334. DOI: 10.1186/s12883-019-1469-1.

Urinary Proteomics in Biomarker Discovery of Kidney-Related Disorders: Diabetic Nephropathy and Drug-Induced Nephrotoxicity in Chronic Headache.

Bellei E, Monari E, Bergamini S, Pini L, Aldo T, Ozben T EJIFCC. 2018; 29(4):290-297.

PMID: 30574040 PMC: 6295592.

References

Kamijo-Ikemori A, Sugaya T, Matsui K, Yokoyama T, Kimura K . Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrology (Carlton). 2011; 16(6):539-44. DOI: 10.1111/j.1440-1797.2011.01469.x. View

Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T . Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006; 284(1-2):175-82. DOI: 10.1007/s11010-005-9047-9. View

Miyata T, Jadoul M, Kurokawa K, Van Ypersele De Strihou C . Beta-2 microglobulin in renal disease. J Am Soc Nephrol. 1998; 9(9):1723-35. DOI: 10.1681/ASN.V991723. View

Bradford M . A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-54. DOI: 10.1016/0003-2697(76)90527-3. View

Dieterle F, Perentes E, Cordier A, Roth D, Verdes P, Grenet O . Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol. 2010; 28(5):463-9. DOI: 10.1038/nbt.1622. View

Ferrari A, Savino G, Gallesi D, Pinetti D, Bertolini A, Sances G . Effect of overuse of the antimigraine combination of indomethacin, prochlorperazine and caffeine (IPC) on the disposition of its components in chronic headache patients. Pharmacol Res. 2006; 54(2):142-9. DOI: 10.1016/j.phrs.2006.03.022. View

Taber S, Pasko D . The epidemiology of drug-induced disorders: the kidney. Expert Opin Drug Saf. 2008; 7(6):679-90. DOI: 10.1517/14740330802410462. View

Hortin G, Sviridov D . Analysis of molecular forms of albumin in urine. Proteomics Clin Appl. 2010; 2(7-8):950-5. DOI: 10.1002/prca.200780145. View

Bolisetty S, Agarwal A . Urine albumin as a biomarker in acute kidney injury. Am J Physiol Renal Physiol. 2011; 300(3):F626-7. PMC: 3064133. DOI: 10.1152/ajprenal.00004.2011. View

10.

Norden A, Fulcher L, Lapsley M, FLYNN F . Excretion of beta 2-glycoprotein I (apolipoprotein H) in renal tubular disease. Clin Chem. 1991; 37(1):74-7. View

11.

Sleno L, Emili A . Proteomic methods for drug target discovery. Curr Opin Chem Biol. 2008; 12(1):46-54. DOI: 10.1016/j.cbpa.2008.01.022. View

12.

. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 Suppl 1:9-160. DOI: 10.1111/j.1468-2982.2003.00824.x. View

13.

Khan T, Sinniah R . Renal tubular antiproteinase (alpha-1-antitrypsin and alpha-1-antichymotrypsin) response in tubulo-interstitial damage. Nephron. 1993; 65(2):232-9. DOI: 10.1159/000187480. View

14.

Meng I, Dodick D, Ossipov M, Porreca F . Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. Cephalalgia. 2011; 31(7):851-60. PMC: 5697138. DOI: 10.1177/0333102411402367. View

15.

Roelofsen H, Alvarez-Llamas G, Schepers M, Landman K, Vonk R . Proteomics profiling of urine with surface enhanced laser desorption/ionization time of flight mass spectrometry. Proteome Sci. 2007; 5:2. PMC: 1783644. DOI: 10.1186/1477-5956-5-2. View

16.

Waring W, Moonie A . Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila). 2011; 49(8):720-8. DOI: 10.3109/15563650.2011.615319. View

17.

Bellei E, Cuoghi A, Monari E, Bergamini S, Fantoni L, Zappaterra M . Proteomic analysis of urine in medication-overuse headache patients: possible relation with renal damages. J Headache Pain. 2011; 13(1):45-52. PMC: 3253154. DOI: 10.1007/s10194-011-0390-9. View

18.

Markoff A, Gerke V . Expression and functions of annexins in the kidney. Am J Physiol Renal Physiol. 2005; 289(5):F949-56. DOI: 10.1152/ajprenal.00089.2005. View

19.

Bellei E, Monari E, Bergamini S, Ozben T, Tomasi A . Optimizing protein recovery yield from serum samples treated with beads technology. Electrophoresis. 2011; 32(12):1414-21. DOI: 10.1002/elps.201000699. View

20.

Nakayama H, Echizen H, Gomi T, Shibuya Y, Nakamura Y, Nakano K . Urinary lipocalin-type prostaglandin D synthase: a potential marker for early gentamicin-induced renal damage?. Ther Drug Monit. 2009; 31(1):126-30. DOI: 10.1097/FTD.0b013e31819566f1. View